Novavax, Inc. (NVAX)

NMS – Real vaqt narxi. Valyuta: USD

7.96

+0.01 (0.13%)

Bozor ochiq: Aug 12, 2026, 1:14 PM EDT

7.92

-0.03 (-0.38%)

Oldingi bozordan keyin: Aug 11, 2026, 7:56 PM EDT

07.08.2026

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.

07.08.2026

Novavax Q2 Earnings Call Highlights

Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant platform and continued cost reductions.

06.08.2026

Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript

06.08.2026

Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

Novavax (NVAX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to earnings of $0.62 per share a year ago.

06.08.2026

Are Medical Stocks Lagging Novavax (NVAX) This Year?

Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

06.08.2026

Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand

Novavax raised its annual revenue forecast after beating quarterly expectations on Thursday, as the vaccine maker's licensing-driven milestone payments helped offset waning demand.

06.08.2026

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax Multiple partner-led experiments with Matrix-M are currently underway in a wide array of infectious disease and oncology targets On track to advance C. difficile vaccine program into the clinic as early as 2027 GAITHERSBURG, Md.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Novavax, Inc. (NVAX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Novavax, Inc. (NVAX)

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax Q2 Earnings Call Highlights

Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript

Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

Are Medical Stocks Lagging Novavax (NVAX) This Year?

Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Videolar

No Data

Press-relizlar

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax Q2 Earnings Call Highlights

Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript

Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

Are Medical Stocks Lagging Novavax (NVAX) This Year?

Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Videolar

No Data

Press-relizlar

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Search stocks

Novavax, Inc. (NVAX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Novavax, Inc. (NVAX)

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax Q2 Earnings Call Highlights

Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript

Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

Are Medical Stocks Lagging Novavax (NVAX) This Year?

Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Videolar

No Data

Press-relizlar

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax Q2 Earnings Call Highlights

Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript

Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

Are Medical Stocks Lagging Novavax (NVAX) This Year?

Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Videolar

No Data

Press-relizlar

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights